Pharmas In China Should Be Mindful Of Cash Flow Risk Amid Rampant Capital Lending
This article was originally published in PharmAsia News
Executive Summary
An expert advised that drug delivery companies in China should pay constant attention to their cash flow amid rampant capital lending by banks under the regulators' loose credit control